Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
Konstantinidou M., Zarganes-Tzitzikas T., Magiera-Mularz K., Holak TA., Dömling A.
The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.